Narrow HCC CheckMate-459 Miss For Opdivo Points The Way For Combos, Roche Shows How

 
• By Alexandra Shimmings

Full data at ESMO show Opdivo managed to scrape a tolerability edge over standard-of-care sorafenib in liver cancer, but eyes were drawn to Roche’s early study of Tecentriq/Avastin as the way forward in this difficult-to-treat cancer.

liver
IO combination therapy may be best in liver cancer. • Source: Shutterstock

More from Clinical Trials

More from R&D